Omar Habibeh1, Khaled Elsayad2, Jan Kriz2, Uwe Haverkamp2, Hans Theodor Eich2. 1. Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. Omar.Habibeh@ukmuenster.de. 2. Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany.
Abstract
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLDs) are aggressive malignancies which represent one of the major post-transplant complications. However, treatment options vary significantly and localized disease may be curatively treated with radiotherapy (RT) or surgery. We report a case of recurrent rectal PTLD, which was successfully treated by chemoimmunotherapy followed by RT. CASE PRESENTATION: We describe a patient who developed a rectal lymphoproliferative lesion 11 years after kidney transplant, which was successfully treated with consolidative RT using 25.4 Gy sequential to chemoimmunotherapy (R-CHOP). RT was well tolerated and the patient showed no signs of grade 3 or 4 toxicity. This patient is free of recurrence 52 months after RT, with an overall survival of 62 months since diagnosis. CONCLUSION: Conventionally fractionated moderate-dose RT appears to be a tolerable and effective treatment option for localized PTLD if a sufficient systemic treatment cannot be applied.
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLDs) are aggressive malignancies which represent one of the major post-transplant complications. However, treatment options vary significantly and localized disease may be curatively treated with radiotherapy (RT) or surgery. We report a case of recurrent rectal PTLD, which was successfully treated by chemoimmunotherapy followed by RT. CASE PRESENTATION: We describe a patient who developed a rectal lymphoproliferative lesion 11 years after kidney transplant, which was successfully treated with consolidative RT using 25.4 Gy sequential to chemoimmunotherapy (R-CHOP). RT was well tolerated and the patient showed no signs of grade 3 or 4 toxicity. This patient is free of recurrence 52 months after RT, with an overall survival of 62 months since diagnosis. CONCLUSION: Conventionally fractionated moderate-dose RT appears to be a tolerable and effective treatment option for localized PTLD if a sufficient systemic treatment cannot be applied.
Authors: Mani Akhtari; Jay Paul Reddy; Chelsea C Pinnix; Pamela K Allen; Eleanor M Osborne; Jillian R Gunther; Sarah A Milgrom; Grace L Smith; Christine F Wogan; Nathan Fowler; Maria Alma Rodriguez; Bouthaina Dabaja Journal: Leuk Lymphoma Date: 2015-05-12
Authors: Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-01 Impact factor: 7.038
Authors: Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin Journal: Radiother Oncol Date: 2011-06-12 Impact factor: 6.280
Authors: Judith M Timms; Andrew Bell; Joanne R Flavell; Paul G Murray; Alan B Rickinson; Alexandra Traverse-Glehen; Françoise Berger; Henri-Jacques Delecluse Journal: Lancet Date: 2003-01-18 Impact factor: 79.321